When was Aurelia Bioscience founded?

Aurelia Bioscience was founded in 2010.

Where is Aurelia Bioscience located?

Aurelia Bioscience is headquartered in Nottingham, United Kingdom.

How many employees does Aurelia Bioscience have?

As of Apr 30, 2026, the latest employee count at Aurelia Bioscience is 2.

Is Aurelia Bioscience a funded company?

Aurelia Bioscience is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Aurelia Bioscience rank among its competitors?

Aurelia Bioscience ranks 35th amongst 90 active competitors, of which 13 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Genoskin, which secured $5.4M in Sep, 2025.

Who are the top competitors of Aurelia Bioscience?

Aurelia Bioscience's top competitors include Magnitude Biosciences, Genoskin and Cayman Chem. Among them, Genoskin secured the most recent funding round in September, 2025.

Aurelia Bioscience - 2026 Company Profile, Team & Competitors

Aurelia Bioscience is an acquired company based in Nottingham (United Kingdom), founded in 2010 by Kathy Dodgson and Gary Allenby. It operates as a CRO offering a wide range of in vitro assays for drug screening. The company has 90 active competitors, including 13 funded and 8 that have exited. Its top competitors include companies like Magnitude Biosciences, Genoskin and Cayman Chem.

Company Details

Aurelia Bioscience offers a range of in vitro assays for drug screening. Founded by former employees of companies such as Roche, Smith Kline Beecham, Glaxo-Wellcome, AstraZeneca, the company claims that its scientists have over 100 years of drug discovery experience. Their drug screening portfolio includes cell based, biochemical, (also in HTS formats) and phenotypic screening services. Aurelia also offers label-free and high content screening, FLIPR screening, FMAT screening, western assay systems and qPCR facilities. The company also offers cell culture services such as plated and grown cells in 96, 384 and 1536 well plates (using liquid handling techniques), sub-culturing, harvesting and cryopreservation. Aurelia claims to have worked with CHO, HEK-293, Hela, SHSY5Y adherent cells and non-adherent cells.

Key Metrics

Founded Year

2010

Location

Nottingham, United Kingdom

Stage

Acquired

Ranked

35^th among 90 active competitors

Employee Count

2 as on Apr 30, 2026

Similar Companies

Magnitude Biosciences & 99 more

Exit Details

Acquired by Charnwood Molecular (Jun 21, 2021)

View Aurelia Bioscience's full profile

Aurelia Bioscience got acquired by Charnwood Molecular on Jun 21, 2021.

Click here to take a look at Aurelia Bioscience's acquisition in detail

Aurelia Bioscience has not raised any funding rounds yet.

The founders of Aurelia Bioscience are Kathy Dodgson and Gary Allenby.

Here are the details of Aurelia Bioscience's key team members:

Kathy Dodgson: Co-Founder of Aurelia Bioscience.
Gary Allenby: Co-Founder of Aurelia Bioscience.

View details of Aurelia Bioscience's Founder profiles and Board Members

Aurelia Bioscience's employee count trend

Aurelia Bioscience has 2 employees as of Apr 26. Here is Aurelia Bioscience's employee count trend over the years:

Employee count trend for Aurelia Bioscience

Uncover Aurelia Bioscience's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Aurelia Bioscience include Magnitude Biosciences, Genoskin and Cayman Chem. Here is the list of Top 10 competitors of Aurelia Bioscience, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Magnitude Biosciences 2018, Durham (United Kingdom), Seed	Provider of cell-free in vitro assay for drug discovery companies	$2.6M	Northstar Ventures, Saker Capital & 10 others	58/100
2nd	Genoskin 2011, Toulouse (France), Series A	In vitro human skin models for preclinical toxicity and efficacy testing	$5.4M	OCCTE, Grand Sud Ouest Capital & 7 others	54/100
3rd	Cayman Chem 1980, Ann Arbor (United States), Funding Raised	Develops bioreagents and offers preclinical services	-	Tehnopol Startup Incubator, Broadoak Capital Partners ... & 2 others	50/100
4th	Reaction Biology 2001, United States, Late Stage	In vitro enzyme activity assays, secializing in kinase & epigenetic HTS and profiling	-	Cobepa, National Cancer Institute & 6 others	40/100
5th	Quantumcyte 2013, Sunnyvale (United States), Seed	Drug assay system to treat cancer	$1.3M	IndieBio, Bayes Ventures	40/100
6th	Radiant Research Services 2009, Bengaluru (India), Acquired	Preclinical in vitro testing and development services	-	-	39/100
7th	Discovery Biomed 2007, Birmingham (United Kingdom), Acquired	Contract research organization	-	NIH, NIDDK & 4 others	39/100
8th	Syntax Bio 2018, Chicago (United States), Unfunded	Preclinical-stage biotech company that develops innovative stem cell-derived therapies by leveraging CRISPR technology	-	-	35/100
9th	Leadgene Biomedical 2013, Tainan (Taiwan), Unfunded	CRO offers invitro drug testing services	-	-	35/100
10th	Orient Gene Biotech 2005, China, Unfunded	Manufactrurer and R&D of in vitro diagnostic reagents	-	-	34/100
35th	Aurelia Bioscience 2010, Nottingham (United Kingdom), Acquired	CRO offering a wide range of in vitro assays for drug screening	-	-	26/100